<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109330</article-id><article-id pub-id-type="publisher-id">ACM-37839</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_58754242.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  外阴原发性乳腺癌1例报告附文献复习
  Primary Breast Cancer of Vulva: A Case Report with Reviewing the Literature
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>琰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>江</surname><given-names>晓虹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>信佳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>莉金</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贾</surname><given-names>清玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>崔</surname><given-names>欢亮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>园园</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院肿瘤放疗科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2185</fpage><lpage>2188</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：报告1例罕见的外阴原发性乳腺癌并结合文献讨论其诊断及治疗方法。方法：以病例报告的方式，结合国外文献复习，综合分析外阴原发性乳腺癌的诊断及治疗。结果：外阴原发性乳腺癌的诊断主要以组织病理学为依据，以手术治疗、化疗、放疗、内分泌治疗、靶向治疗或免疫治疗为主要治疗方法。结论：外阴原发性乳腺癌的诊断需排除外阴转移性乳腺癌及其他外阴原发疾病，以手术治疗为主，根据组织病理学特性选择合适的辅助治疗。
    Objective: To report a rare case of vulvar primary breast cancer and discuss its diagnosis and treatment combined with literature. Methods: The diagnosis and treatment of vulvar primary breast cancer were analyzed by case report and review of foreign literature. Results: The diagnosis of vulvar primary breast cancer was mainly based on histopathology, and the main treatment was surgical treatment, chemotherapy, radiotherapy, endocrine treatment, targeted treatment or immunotherapy. Conclusion: The diagnosis of vulvar primary breast cancer needs to exclude the metastatic breast cancer and other vulvar primary diseases. The main treatment is surgery, and the appropriate adjuvant treatment is selected according to the histopathological characteristics. 
  
 
</p></abstract><kwd-group><kwd>外阴癌，乳腺型，诊断，治疗, Vulvar Cancer</kwd><kwd> Breast</kwd><kwd> Diagnosis</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：报告1例罕见的外阴原发性乳腺癌并结合文献讨论其诊断及治疗方法。方法：以病例报告的方式，结合国外文献复习，综合分析外阴原发性乳腺癌的诊断及治疗。结果：外阴原发性乳腺癌的诊断主要以组织病理学为依据，以手术治疗、化疗、放疗、内分泌治疗、靶向治疗或免疫治疗为主要治疗方法。结论：外阴原发性乳腺癌的诊断需排除外阴转移性乳腺癌及其他外阴原发疾病，以手术治疗为主，根据组织病理学特性选择合适的辅助治疗。</p></sec><sec id="s2"><title>关键词</title><p>外阴癌，乳腺型，诊断，治疗</p></sec><sec id="s3"><title>Primary Breast Cancer of Vulva: A Case Report with Reviewing the Literature</title><p>Yan Luo<sup>*</sup>, Xiaohong Jiang<sup>*</sup>, Xinjia He, Li Yu, Lijin Zhu, Qingyu Jia, Huanliang Cui, Yuanyuan Zhao<sup>#</sup></p><p>Affiliated Hospital of Qingdao University Department of tumor radiotherapy, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/50-1571578x4_hanspub.png" /></p><p>Received: Sep. 4<sup>th</sup>, 2020; accepted: Sep. 18<sup>th</sup>, 2020; published: Sep. 25<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/50-1571578x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To report a rare case of vulvar primary breast cancer and discuss its diagnosis and treatment combined with literature. Methods: The diagnosis and treatment of vulvar primary breast cancer were analyzed by case report and review of foreign literature. Results: The diagnosis of vulvar primary breast cancer was mainly based on histopathology, and the main treatment was surgical treatment, chemotherapy, radiotherapy, endocrine treatment, targeted treatment or immunotherapy. Conclusion: The diagnosis of vulvar primary breast cancer needs to exclude the metastatic breast cancer and other vulvar primary diseases. The main treatment is surgery, and the appropriate adjuvant treatment is selected according to the histopathological characteristics.</p><p>Keywords:Vulvar Cancer, Breast, Diagnosis, Treatment</p><disp-formula id="hanspub.37839-formula49"><graphic xlink:href="//html.hanspub.org/file/50-1571578x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/50-1571578x8_hanspub.png" /> <img src="//html.hanspub.org/file/50-1571578x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>人类胚胎从第5周开始，外胚层乳腺条纹在胚胎干上发育，在胚胎腹表面形成乳腺嵴，沿着乳线从两侧腋窝向腹股沟延伸，包括外阴。乳腺嵴通常在几个月内消退，只在前胸形成正常的乳腺组织。少数情况下，乳线上的某一点乳腺嵴未消退，从而形成异位乳腺组织 [<xref ref-type="bibr" rid="hanspub.37839-ref1">1</xref>]，其与正常乳房有相同的生理及病理变化。仅有1%的人可发生异位乳腺组织，而外阴原发的乳腺癌更是极为罕见 [<xref ref-type="bibr" rid="hanspub.37839-ref2">2</xref>]。</p></sec><sec id="s6"><title>2. 病例资料</title><p>患者女性，63岁，9年前发现左侧大阴唇有大小约0.5 cm结节，无明显不适，后该外阴病变逐渐变硬、增大，伴瘙痒。于2019年2月行超声检查，提示阴蒂恶性肿瘤并左侧腹股沟区转移性淋巴结。2019年3月4日行PET/CT示：外阴癌并左侧髂血管走行区、左侧腹股沟区淋巴结转移、右侧髂骨及右侧第7肋骨转移，乳房及腋窝无可疑病变。于2019年3月行外阴广泛切除术加左侧腹股沟淋巴结清扫术，组织病理学示：外阴浸润性癌。免疫组化示：p40 (−)，CK7 (+)，CKpan (+)，ER局灶(+，&lt;10%)，PR (−)，AR (+)，GATA3 (+)，CD31及D2-40示间质脉管癌栓(+)，Ki-67 (+)约30%，S100示神经侵犯(−)，HER2 (−)。结合免疫组化，考虑乳腺型腺癌。术后经多学科会诊，诊断该病例为外阴原发性乳腺癌。2019年4月10日至2019年7月3日患者接受了4个周期环磷酰胺和表柔比星方案(AC)化疗，2019年7月25日至2019年8月26日行盆腔及腹股沟淋巴结引流区放疗(总剂量6-MV X线DT 5000cGy)，2019年9月27日复查上腹部增强CT示：新发肝脏多发转移瘤，考虑进展，于2019年9月30日至2019年12月24日行4个周期二线卡培他滨和白蛋白紫杉醇方案(TX)化疗，3周期化疗后复查胸部、上腹部、下腹部及盆腔增强CT，疗效评价为部分缓解。</p></sec><sec id="s7"><title>3. 讨论</title><sec id="s7_1"><title>3.1. 诊断</title><p>从已被报道的外阴原发性乳腺癌病例来看，最常见的临床表现为缓慢增长的无痛性外阴结节，以大阴唇原发多见 [<xref ref-type="bibr" rid="hanspub.37839-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.37839-ref4">4</xref>]，且发病年龄为与乳腺癌一致。该病的诊断主要依据为组织病理学，通过病史、体格检查和影像学检查排除乳房原发性病变，且需与浸润性Paget病、转移性乳腺癌、原发性皮肤附件癌、原发性大、小前庭腺癌相鉴别。同时完善全身检查明确是否有远处转移。</p></sec><sec id="s7_2"><title>3.2. 治疗</title><p>由于外阴原发的乳腺癌极为罕见，并无标准的治疗模式，我们建议以乳腺癌的治疗原则进行治疗，以外科手术治疗为主，包括根治性外阴切除术或相关的腹股沟淋巴结清扫术。根据患者个人情况决定是否行辅助化疗、放疗、内分泌治疗、靶向治疗或免疫治疗。</p><p>结合患者PET/CT及免疫组化结果，该病例患者已明确诊断为IV期外阴原发性三阴性乳腺型腺癌，接受外阴广泛切除术及腹股沟淋巴结清扫术后行术后辅助化疗及放疗。有研究表明，ER、PR和HER2受体的表达在乳腺癌原发灶和转移灶之间可能存在显著不一致性，可影响转移性乳腺癌预后 [<xref ref-type="bibr" rid="hanspub.37839-ref5">5</xref>]。因此，建议该患者行转移灶免疫组化检查，若ER或PR呈阳性，化疗结束后可行至少5年内分泌治疗，结合患者已绝经状态，推荐使用第三代芳香化酶抑制剂类药物，包括来曲唑、阿那曲唑、依西美坦。若HER为阳性，则应尽早使用曲妥珠单抗靶向治疗，标准用药时间为1年。免疫治疗是乳腺癌的一种新的治疗方法，癌细胞可通过操纵程序性细胞死亡蛋白1 (PD-1)及其配体程序性死亡配体1 (PD-L1)从而介导免疫逃逸，避免免疫系统发现和根除癌细胞，其中PD-1和PDL1可作为T细胞激活的负调节因子而起到免疫调节作用 [<xref ref-type="bibr" rid="hanspub.37839-ref6">6</xref>]。而单克隆抗体可有效抑制这些调节免疫激活的免疫检查点，用于治疗三阴性乳腺癌 [<xref ref-type="bibr" rid="hanspub.37839-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.37839-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.37839-ref9">9</xref>]。有研究表明，联合应用Atezolizumab (抗PD-L1)和白蛋白紫杉醇成为目前治疗转移性PD-L1阳性的三阴性乳腺癌一线治疗标准 [<xref ref-type="bibr" rid="hanspub.37839-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.37839-ref11">11</xref>]。因此，本病例患者可行PD-L1检测，如果原发肿瘤或远处转移部位中有至少一个肿瘤样本显示PD-L1阳性，建议添加Atezolizumab免疫治疗。</p></sec></sec><sec id="s8"><title>4. 结论</title><p>综上所述，在诊断外阴原发性乳腺癌前，需与外阴转移性乳腺癌及其他原发于外阴的疾病相鉴别。外阴原发性乳腺癌发生率极低，在已报道的病例中，该病的治疗都是由乳腺癌的治疗原则推断而来，包括手术治疗、化疗、放疗、内分泌治疗、靶向治疗及免疫治疗。一旦确诊，应根据肿瘤的分期及组织病理学特性选择合适的治疗方法 [<xref ref-type="bibr" rid="hanspub.37839-ref12">12</xref>]。这种罕见疾病目前尚无明确治疗标准，然而，Atezolizumab联合白蛋白紫杉醇作为转移性PD-L1阳性的三阴性乳腺癌一线治疗方案，或可成为外阴原发性乳腺癌PD-L1阳性患者治疗的合理开端。</p><p>注：该病例报道已获得病人的知情同意。</p></sec><sec id="s9"><title>文章引用</title><p>罗 琰,江晓虹,何信佳,于 丽,朱莉金,贾清玉,崔欢亮,赵园园. 外阴原发性乳腺癌1例报告附文献复习Primary Breast Cancer of Vulva: A Case Report with Reviewing the Literature[J]. 临床医学进展, 2020, 10(09): 2185-2188. https://doi.org/10.12677/ACM.2020.109330</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37839-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Fracchioli, S., Puopolo, M., De La Longrais, I.A., Scozzafava, M., Bogliatto, F., Arisio, R., Micheletti, L. and Katsaros, D. (2006) Primary “Breast-Like” Cancer of the Vulva: A Case Report and Critical Review of the Literature. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 423-428.</mixed-citation></ref><ref id="hanspub.37839-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Grossl, N. (2000) Supernumerary Breast Tissue: Historical Perspectives and Clinical Features. Southern Medical Journal, 93, 29-32. &lt;br&gt;https://doi.org/10.1097/00007611-200001000-00004</mixed-citation></ref><ref id="hanspub.37839-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Simon, K.E., Dutcher, J.P., Runowicz, C.D. and Wiernik, P.H. (1988) Adenocarcinoma Arising in Vulvar Breast Tissue. Cancer, 62, 2234-2238.  
&lt;br&gt;https://doi.org/10.1002/1097-0142(19881115)62:10&lt;2234::AID-CNCR2820621027&gt;3.0.CO;2-F</mixed-citation></ref><ref id="hanspub.37839-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Lopes, A., Louis, J.St., Balancin, M.L., Barbosa, E.M., Costa, R.L.R., et al. (2018) A Rare Presentation of Primary Breast Carcinoma in the Vulva: A Case Report and Literature Review. Clinical Breast Cancer, 18, e291-e294.  
&lt;br&gt;https://doi.org/10.1016/j.clbc.2017.06.004</mixed-citation></ref><ref id="hanspub.37839-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Z., Li, N., Li, X., Lei, L. and Wang, X. (2020) The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients. OncoTargets and Therapy, 13, 853-863.  
&lt;br&gt;https://doi.org/10.2147/OTT.S231493</mixed-citation></ref><ref id="hanspub.37839-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Vinay, D.S. and Kwon, B.S. (2018) Harnessing Immune Checkpoints for Cancer Therapy. Immunotherapy, 10, 1265-1284.  
&lt;br&gt;https://doi.org/10.2217/imt-2017-0168</mixed-citation></ref><ref id="hanspub.37839-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science (New York, NY), 359, 1350-1355. &lt;br&gt;https://doi.org/10.1126/science.aar4060</mixed-citation></ref><ref id="hanspub.37839-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wei, P.C., Duffy, C.R. and Allison, J.P. (2018) Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. &lt;br&gt;https://doi.org/10.1158/2159-8290.CD-18-0367</mixed-citation></ref><ref id="hanspub.37839-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Marra, A., Viale, G. and Curigliano, G. (2019) Recent Advances in Triple Negative Breast Cancer: The Immunotherapy Era. BMC Medicine, 17, 90. &lt;br&gt;https://doi.org/10.1186/s12916-019-1326-5</mixed-citation></ref><ref id="hanspub.37839-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Schmid, P., Rugo, H.S., Adams, S., Schneeweiss, A., et al. (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England Journal of Medicine, 379, 2108-2121.</mixed-citation></ref><ref id="hanspub.37839-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Schmid, P., Rugo, H.S., Adams, S., Schneeweiss, A., et al. (2020) Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 44-59.</mixed-citation></ref><ref id="hanspub.37839-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Intra, M., Maggioni, A., Sonzogni, A., DE Cicco, C., Machado, L.S., Sagona, A. and Talakhadze, N. (2006) A Rare Association of Synchronous Intraductal Carcinoma of the Breast and Invasive Carcinoma of Ectopic Breast Tissue of the Vulva: Case Report and Literature Review. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 428-433.</mixed-citation></ref></ref-list></back></article>